BidaskClub lowered shares of Neurocrine Biosciences (NASDAQ:NBIX) from a buy rating to a hold rating in a research note issued to investors on Saturday morning.

Other equities analysts have also recently issued research reports about the company. Stifel Nicolaus began coverage on Neurocrine Biosciences in a report on Tuesday, August 7th. They issued a buy rating and a $137.00 price target for the company. Jefferies Financial Group upped their price target on Neurocrine Biosciences to $124.00 and gave the stock a buy rating in a report on Monday, July 30th. Barclays set a $100.00 price target on Neurocrine Biosciences and gave the stock a buy rating in a report on Friday, June 8th. Oppenheimer set a $140.00 price target on Neurocrine Biosciences and gave the stock a buy rating in a report on Tuesday, September 4th. Finally, TheStreet upgraded Neurocrine Biosciences from a d+ rating to a c rating in a report on Friday, August 3rd. One equities research analyst has rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Neurocrine Biosciences currently has an average rating of Buy and an average target price of $121.83.

Shares of NASDAQ:NBIX opened at $117.36 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 9.19 and a quick ratio of 9.19. Neurocrine Biosciences has a 1 year low of $55.95 and a 1 year high of $126.98. The stock has a market cap of $11.01 billion, a PE ratio of -72.44, a PEG ratio of 38.39 and a beta of 0.42.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, July 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.11. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The business had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $84.11 million. During the same quarter in the previous year, the business earned ($0.68) EPS. The company’s revenue for the quarter was up 1428.4% on a year-over-year basis. sell-side analysts forecast that Neurocrine Biosciences will post 0.15 EPS for the current year.

In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 23,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The stock was sold at an average price of $105.00, for a total value of $2,415,000.00. Following the transaction, the insider now directly owns 105,942 shares of the company’s stock, valued at approximately $11,123,910. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Dimitri E. Grigoriadis sold 23,022 shares of the company’s stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $110.00, for a total value of $2,532,420.00. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Mainstay Capital Management LLC ADV raised its position in shares of Neurocrine Biosciences by 3,156.2% in the 2nd quarter. Mainstay Capital Management LLC ADV now owns 134,970 shares of the company’s stock valued at $1,624,000 after purchasing an additional 130,825 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $334,000. Global X Management Co LLC raised its position in shares of Neurocrine Biosciences by 7.4% in the 2nd quarter. Global X Management Co LLC now owns 10,068 shares of the company’s stock valued at $989,000 after purchasing an additional 694 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Neurocrine Biosciences by 102.2% in the 2nd quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,489 shares of the company’s stock valued at $245,000 after purchasing an additional 1,258 shares in the last quarter. Finally, Orbimed Advisors LLC raised its position in shares of Neurocrine Biosciences by 83.7% in the 2nd quarter. Orbimed Advisors LLC now owns 137,800 shares of the company’s stock valued at $13,537,000 after purchasing an additional 62,800 shares in the last quarter.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C.

Further Reading: Understanding Relative Strength Index

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.